Loading page...
Loading page...
This round is closed. Synced from the EU Funding & Tenders Portal on 9 November 2026.
Based on projects the EU funded on the same subject in this programme.
COMBINE-CTCombining CT diagnostic data and interventional approaches for futureproof cardiology care
HORIZON-JU-IHI-2022-03-03 · 2023 · Official record ↗
PFAROSDriving Sustainable Innovation to Minimise PFAS in European Healthcare
HORIZON-JU-IHI-2025-10-03-two-stage · 2026 · Official record ↗
EXIT-CVDEXIT-CVD
HORIZON-JU-IHI-2025-09-01-single-stage · 2026 · Official record ↗
INTERCEPTVerification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing INTERCEPTION of full-blown disease development
HORIZON-JU-IHI-2024-07-03-singe-stage · 2025 · Official record ↗
EASYGENEASY workflow integration for GENe therapy
HORIZON-JU-IHI-2024-07-02-singe-stage · 2025 · Official record ↗
AD-RIDDLEREAL-WORLD IMPLEMENTATION, DEPLOYMENT AND VALIDATION OF EARLY DETECTION TOOLS AND LIFESTYLE ENHANCEMENT
HORIZON-JU-IHI-2022-03-01 · 2024 · Official record ↗
6G-CARE6G-enabled Connected and Autonomous Response for eHealth
HORIZON-JU-SNS-2025-02-STREAM-D-01 · 2026 · Official record ↗
Project-COMFORTPatient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)
HORIZON-JU-IHI-2023-04-02-two-stage · 2024 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
The action under this topic is expected to achieve the following impacts:
The action will also support the EU political priority to boost European competitiveness and contribute to a number of European policies/initiatives, which include the European Commission’s European Health Data Space Regulation (EHDS)1 and the EU Artificial Intelligence Act2.
1 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L_202500327
2 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689
With advances in clinical and surgical techniques, medical technology, pain management as well as pre- and post-surgical care, more procedures that have been traditionally performed in hospital settings can now be performed in facilities outside hospitals with no overnight stays required, easing the demand on overstretched hospitals and reducing hospital acquired infections. These facilities are referred to as ambulatory surgical centres (ASCs).
The actions under this topic contribute to all the following outcomes:
Target group for the outcomes are:
The EU’s ageing population and a rising burden of diseases and disorders, in particular noncommunicable diseases (such as cardiometabolic diseases, cancers, neurodegenerative or musculoskeletal disorders), have resulted in increasing health care costs and limited procedural capacity in operating rooms and cath labs (catheterisation laboratory). Lack of specialists is also an issue. This delays patient access to health care and increases the need for alternative and more cost-effective forms of care [5]. The shift of inpatient surgeries and treatments to ambulatory surgical centres (ASCs) could potentially provide a solution to the hospital capacity problem as well as reducing hospital acquired complications and providing improved access to healthcare services for patients in rural areas. ASCs are healthcare facilities focused on providing same-day surgical care, including diagnostic and preventative procedures for patients who do not require overnight stays. It is believed that ASCs can transform the outpatient experience for patients by providing them with a more convenient alternative to hospital-based outpatient procedures. ASCs can be operated by private or public healthcare services.
Numerous factors influence whether surgical procedures can be carried out within ambulatory surgical centres. The key drivers are changes and further development in clinical practice and medical technology. The action funded under this topic will be focused on ASCs specialised in orthopaedics for knee and hip joint replacement surgery as well as ASCs specialised in cardiology for cardiac ablation procedures and elective rhythmology. All of these procedures are elective and will increase in the next years due to the ageing population, improved diagnostics and extension of medical guidelines. Based on patient selection, these procedures have been proven suitable for ambulatory settings. This is reinforced by the downward trend in length of stay in hospitals for these procedures in recent years. This also reflects developments in medical technology in these procedures over the last years, that have led to more precise, faster, easier, gentler and more patient-specific interventions. Shifting those procedures from hospitals into ASCs can help to relieve inpatient capacities, enabling faster patient access to those surgeries and in the end reducing overall health care costs. It is important to stress that treatment in ASCs requires good patient selection prior to the surgery based on medical classifications – like the American Society of Anaesthesiologists’ risk classification for estimating the perioperative risk – and social factors, such as the individual domestic situation of the patient, to make the intervention in ASC successful. Severe and complicated cases will still have to be treated in hospitals.
ASCs offer a lot of benefits to the health care system and can address some problems associated with inpatient treatments in hospitals. Studies show that outpatient procedures are safe and can achieve similar or superior functional outcomes compared to inpatient procedures and, for example, the early mobilisation facilitated by outpatient pathway in hip and knee replacement surgeries contributes to faster recovery timelines [1] [2].
Due to the fact that the costly infrastructure of the hospital is not needed, and patients go home the same day after an outpatient procedure, the shift of procedures into the outpatient setting results in significant cost savings (an outpatient total shoulder arthroplasty (TSA) results in a 40% decrease in charges [3] and unicompartmental knee replacement (UKR) saving up to roughly EUR 18 000 [USD 20 500] per patient [4]). Enhanced healthcare resource utilisation and reduced patient waiting times are additional benefits. Additionally, there are also some patient-related benefits of outpatient procedures. It is proven that patients benefit from recovering in familiar home setting, with various technologies to help monitor their recovery and provide them with access to HCPs. This reduces anxiety [1] and leads to earlier mobility, thus a faster recovery time and a quicker return to daily activities. Overall, this enhances patient satisfaction [1] [2]. On top of that, ASCs decrease the risk of nosocomial infections with the reduced exposure to hospitals environment.
Effective implementation of ASCs faces multiple hurdles including:
Applicants should envisage the following activities as part of the action funded under this topic:
Applicants should consider learnings and synergies with relevant initiatives at national and European level to maximise the potential impact of the future project.
1. Admissibility Conditions: Proposal page limit and layout
Described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
·At stage 1 of a two-stage Call, the limit for RIA short proposals is 20 pages;
·At stage 2 of a two-stage Call, the limit for RIA full proposals is 50 pages.
2. Eligible Countries
Described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
Described in Annex B of the Work Programme General Annexes and in the “Conditions of the Calls for proposals and Call management rules” section of the IHI JU Work Programme (WP).
4. Financial and operational capacity and exclusion
Described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Described in Annex D of the Work Programme General Annexes and in the “Conditions of the Calls for proposals and Call management rules” section of the IHI JU Work Programme (WP).
5b. Evaluation and award: Submission and evaluation processes
Described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Described in Annex G of the Work Programme General Annexes.
Described in the “Conditions of the Calls for proposals and Call management rules” section of the IHI JU Work Programme (WP).
Eligibility conditions for funding exceptions for :
HORIZON-JU-IHI-2025-11-05-two-stage
(Establishing Ortho and Cardiology Ambulatory Surgical Centres in Europe)
Legal entities established in the UK and Canada
Legal entities participating in this topic and established in the UK and Canada are not eligible to receive funding.
Described in the “Conditions of the Calls for proposals and Call management rules” section of the IHI JU Work Programme (WP).
Eligibility conditions for funding exceptions for :
HORIZON-JU-IHI-2025-11-03-two-stage
(AI-Powered Signal Detection in Pharmacovigilance)
Legal entities established in the UK and Canada
Legal entities participating in this topic and established in the UK and Canada are not eligible to receive funding.
DOCUMENTS
Where relevant, templates of the reference documents and associated guidance can be found on the IHI JU website.
Regarding the application forms for submitting proposals, the relevant templates and annexes are available to download in the submission system of the Funding and Tender Opportunities portal.
The IHI JU 11th Call for proposals full topic text is available here.
Evaluation form (single and two-stage Calls)
Evaluation form (Research and Innovation Actions – single and two-stage calls) :
- IHI JU Evaluation form for Research and Innovation Actions (single and two-stage Calls)
Proposal Templates Part A and Part B (Research and Innovation Actions – first and second stage of two-stage calls) :
1. For 1st Stage of two-stage Calls
Please note that only Part A of this template is applicable for this call. For Part B, see point below.
Proposal Annexes:
§ Annex: Type of Participants
The “type of participants” is an IHI specific annex.
The excel template is related to:
Short proposals (first stage of two-stage calls) can be found here and the instructions on how to fill in this template can be found here. 
This is a compulsory annex, and it must be uploaded as a separate document in the submission system.
2. For 2nd Stage of two-stage Calls
Please note that only Part A of this template is applicable for this call. For Part B, see point below.
Proposal Annexes:
§ Annex to the budget and type of participants
The excel document template can be found here.
Instructions on how to fill in the budget can be found here.
Instructions on how to fill the type of participants can be found here.
This is a compulsory annex, which complements the budget figures already included in the proposal budget in PART A. Its purpose is to correctly guide the consortium in providing IHI-specific budget items (e.g. IKOP, IKAA, FC PAID, FC RECEIVED) and to comply with IHI additional eligibility criteria (e.g. 45% industry contribution).
§ Annex: Declaration of in-kind contribution commitment
The “Declaration of in-kind contribution commitment” is an IHI specific annex and it is applicable to the single stage and second stage of two-stage Calls.
The word document template can be found here.
This is a is a compulsory annex and it must be uploaded as a separate document in the submission system.
§ Annex: In-kind contributions to additional activities (IKAA)
The ‘’In-kind contributions to additional activities (IKAA)’’ is an IHI specific annex. The excel template can be found here and the instructions on how to fill in this template can be found here.
This is an optional annex.
§ Annex: Essential information for clinical studies
The information on clinical studies is a Horizon Europe annex.
If your proposal does not include clinical studies, please upload a statement declaring your proposal does not include clinical studies.
The information on clinical studies annex can be found here.
This is a is a compulsory annex and it must be uploaded as a separate document in the submission system.
§ Annex: Ethics
This is a HE annex. Ethics self-assessment should be included in proposal part A. However, in Calls where several serious ethics issues are expected, the characters limit in this section of proposal part A may not be sufficient for participants to give all necessary information. In those cases, participants may include additional information in an annex to proposal part B.
This is an optional annex.
Application and evaluation forms and model grant agreement (MGA):
Model Grant Agreement (MGA)
HE General MGA v1.2
Additional documents:
- Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014 (in short Single Basic Act ‘SBA’ or Council Regulation (EU) 2021/2085).
- IHI JU Work Programme (WP) 
- Strategic Research and Innovation Agenda (SRIA)
- IHI JU Guide for Applicants
- IHI JU FAQs
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.